Strongyloidiasis

Strongyloidiasis is a parasitic infection caused by nematodes of the genus Strongyloides, most notably Strongyloides stercoralis in dogs and cats, and Strongyloides tumefaciens in cats. These are small, thread-like roundworms that reside in the small intestine of their hosts. The disease is characterized by enteritis, diarrhea, and in immunocompromised or young animals, potentially fatal hyperinfection syndrome. Strongyloides species have a unique life cycle that includes both free-living and parasitic stages, with the ability to cause autoinfection, leading to persistent infections and severe clinical disease. The infection is zoonotic, with human cases reported, particularly in tropical and subtropical regions. In veterinary medicine, strongyloidiasis is most commonly diagnosed in young, stressed, or immunocompromised animals, and it is a significant cause of diarrhea in kennels and catteries.

The primary causative agents are Strongyloides stercoralis (dogs, cats, and humans) and Strongyloides tumefaciens (cats). These nematodes belong to the family Strongyloididae. The infectious stage is the filariform larva (L3), which is found in contaminated soil or feces. Transmission occurs via percutaneous penetration of the skin or through ingestion of contaminated food or water. In the host, larvae migrate through the bloodstream to the lungs, ascend the trachea, are swallowed, and reach the small intestine, where they mature into adult females. Adult females reproduce by parthenogenesis, producing eggs that hatch into rhabditiform larvae (L1) in the intestinal lumen. These larvae are passed in feces and can either develop into free-living adults or transform into infective filariform larvae. Autoinfection occurs when rhabditiform larvae molt to filariform larvae within the intestine and penetrate the intestinal wall or perianal skin, leading to internal reinfection and potentially hyperinfection. Virulence factors include the ability to evade host immune responses, particularly through modulation of Th2 responses and production of immunomodulatory molecules. The parasite's proteases facilitate tissue invasion and migration.

Strongyloidiasis is distributed worldwide but is more prevalent in tropical, subtropical, and warm temperate regions. In dogs and cats, infection is more common in young animals, particularly those under 6 months of age, and in animals housed in crowded, unsanitary conditions such as shelters, kennels, and catteries. Certain breeds may have increased susceptibility due to immunogenetic factors, although specific breed predispositions are not well-documented. The prevalence in dogs has been reported to range from 1% to 30% in endemic areas, with higher rates in stray or free-roaming populations. In cats, infection is less common but can be significant in multi-cat environments. The parasite is zoonotic, with human infections occurring through contact with contaminated soil or feces, particularly in immunocompromised individuals. Environmental factors such as warm, moist soil and poor sanitation facilitate transmission. Seasonality may be observed with higher transmission in rainy seasons. In kennel situations, outbreaks can occur due to rapid reinfection and autoinfection.

The pathophysiology of strongyloidiasis involves several stages. Initially, infective filariform larvae penetrate the skin, causing local inflammation and pruritus. Larvae then enter the bloodstream and migrate to the lungs, where they break into alveoli, causing coughing and potential pneumonia. After being coughed up and swallowed, larvae reach the small intestine, where they mature into adult females. Adult worms embed in the intestinal mucosa, causing mechanical damage and inflammation. The host immune response, particularly Th2-mediated, leads to eosinophilia and mast cell activation, contributing to enteritis. The intestinal damage results in malabsorption, protein-losing enteropathy, and diarrhea. In immunocompromised animals or those with concurrent disease, the autoinfection cycle can become amplified, leading to hyperinfection syndrome. This involves massive larval migration through the intestinal wall, causing severe enterocolitis, bacteremia, and dissemination to other organs such as the liver, lungs, and central nervous system. The hyperinfection syndrome is often fatal. Chronic infection can lead to weight loss, anemia, and secondary bacterial infections.

Predisposing factors for strongyloidiasis include young age (especially <6 months), immunosuppression (e.g., due to corticosteroid therapy, concurrent viral infections such as feline leukemia virus or feline immunodeficiency virus, or malnutrition), overcrowding, poor sanitation, and stress. Animals with concurrent gastrointestinal diseases or those on immunosuppressive drugs are at higher risk for hyperinfection. In dogs, certain breeds such as German Shepherds may have a genetic predisposition to immunosuppression, increasing susceptibility. Environmental factors such as warm, humid climates and contaminated soil are critical. In kennels and catteries, high stocking density and inadequate fecal management facilitate transmission. Additionally, animals that are free-roaming or have access to contaminated environments are more likely to be infected.

Clinical signs of strongyloidiasis vary depending on the stage of infection and the host's immune status. In peracute cases, especially in young puppies or kittens, signs may include sudden onset of severe diarrhea, dehydration, and death within days. Acute infection is characterized by mucoid or bloody diarrhea, tenesmus, vomiting, anorexia, and weight loss. Respiratory signs such as coughing and dyspnea may occur during larval migration. Subacute and chronic infections may present with intermittent diarrhea, poor growth, dull hair coat, and mild anemia. In immunocompromised animals, hyperinfection syndrome can cause severe enterocolitis, pneumonia, hepatitis, and neurological signs such as ataxia and seizures. Physical examination may reveal dehydration, pale mucous membranes, fever, and abdominal pain. In cats with Strongyloides tumefaciens, nodular lesions in the colon may be palpated or seen on imaging.

Differential diagnoses for strongyloidiasis include other causes of diarrhea and enteritis in dogs and cats: 1) Other parasitic infections: hookworms (Ancylostoma spp.), whipworms (Trichuris vulpis), coccidia (Isospora spp.), Giardia, and Tritrichomonas foetus. 2) Bacterial enteritis: Salmonella, Campylobacter, Clostridium perfringens, and Escherichia coli. 3) Viral infections: Canine parvovirus, feline panleukopenia, coronavirus. 4) Inflammatory bowel disease (IBD). 5) Dietary indiscretion or food allergy. 6) Exocrine pancreatic insufficiency. 7) Intestinal neoplasia (lymphoma). 8) Intussusception or other mechanical obstructions. Key distinguishing features: parasitic infections often show eosinophilia and larvae on fecal examination; bacterial and viral infections may have systemic signs and specific antigen tests; IBD is diagnosed by biopsy; dietary issues respond to dietary changes; neoplasia may be palpable or seen on imaging.

The diagnostic algorithm for strongyloidiasis begins with a thorough history and physical examination, focusing on age, environment, and clinical signs. The next step is fecal examination using fresh feces. Direct smear may reveal motile larvae, but the Baermann technique is the gold standard for detecting Strongyloides larvae, as it concentrates larvae. Fecal flotation with zinc sulfate or sugar solution can also be used, but larvae are less likely to be seen. In cases of hyperinfection, larvae may be found in bronchoalveolar lavage fluid, tracheal wash, or even in blood smears. Serological tests (ELISA) are available for research but are not widely used in veterinary practice. PCR-based assays on feces are sensitive and specific. If respiratory signs are present, thoracic radiographs may show interstitial or alveolar patterns. In chronic cases, blood work may reveal eosinophilia, hypoalbuminemia, and elevated liver enzymes. Definitive diagnosis is confirmed by identification of larvae in feces or other samples. Treatment should be initiated based on clinical suspicion and positive fecal examination.

Hematology: Eosinophilia is common, especially in early or chronic infections. Anemia may be present due to blood loss from intestinal lesions. Leukocytosis with neutrophilia may occur with secondary bacterial infections. Serum biochemistry: Hypoalbuminemia due to protein-losing enteropathy. Elevated liver enzymes (ALT, AST) may be seen in hyperinfection due to hepatic migration. Electrolyte imbalances (hypokalemia, hyponatremia) due to diarrhea. Urinalysis: Generally unremarkable, but proteinuria may occur if renal involvement. Blood gas analysis: Metabolic acidosis due to diarrhea. Specific biomarkers: Fecal antigen tests (ELISA) for Strongyloides are available in some laboratories. PCR on feces is highly sensitive. Serology for antibodies may be used in research. In hyperinfection, larvae may be detected in blood smears (microfilaria-like).

Radiography: Thoracic radiographs may show a diffuse interstitial or alveolar pattern during larval migration. Abdominal radiographs may reveal gas-filled loops of intestine, but are often nonspecific. Ultrasonography: May show thickened intestinal walls, increased echogenicity of the mucosa, and mesenteric lymphadenopathy. In cats with Strongyloides tumefaciens, colonic nodules may be visible as hypoechoic masses. Computed Tomography (CT): Not commonly used but can provide detailed images of pulmonary and intestinal lesions. Magnetic Resonance Imaging (MRI): Rarely indicated. Endoscopy: Can visualize intestinal mucosa, which may appear erythematous, edematous, or ulcerated. Biopsies can be taken for histopathology. Fluoroscopy: Not typically used.

Cytology: Fine needle aspirates of mesenteric lymph nodes may show eosinophilic inflammation. Bronchoalveolar lavage fluid may contain larvae and eosinophils. Histopathology: Intestinal biopsies reveal eosinophilic and lymphoplasmacytic enteritis, with larvae present in the crypts or mucosa. In hyperinfection, larvae may be seen in the intestinal wall, liver, lungs, and other organs. Special stains such as Giemsa or hematoxylin-eosin can highlight larvae. In cats with Strongyloides tumefaciens, colonic nodules consist of granulomatous inflammation with embedded larvae.

The primary treatment for strongyloidiasis is anthelmintic therapy. The drug of choice is ivermectin (dogs: 0.2-0.4 mg/kg SC or PO, repeated every 2 weeks for 2-3 treatments; cats: 0.2-0.4 mg/kg SC or PO, but caution in kittens). Fenbendazole (50 mg/kg PO q24h for 3-5 days) is also effective. Levamisole (5-8 mg/kg PO) has been used but is less safe. In severe cases, supportive care is essential: intravenous fluids for dehydration and electrolyte imbalances, nutritional support, and treatment of secondary bacterial infections with appropriate antibiotics. In immunocompromised animals, immunosuppressive drugs should be reduced or discontinued if possible. For hyperinfection syndrome, aggressive therapy with ivermectin (0.2-0.4 mg/kg SC or PO, repeated every 48 hours for 2-3 doses) and supportive care is critical. Environmental decontamination is necessary to prevent reinfection.

The prognosis for strongyloidiasis is generally good in immunocompetent animals with early diagnosis and treatment. Most animals respond to anthelmintic therapy within a few days. However, in young, debilitated, or immunocompromised animals, the prognosis is guarded, especially if hyperinfection syndrome develops, which carries a high mortality rate (up to 50-80%). Chronic infections may lead to long-term weight loss and failure to thrive. Recurrence is possible if environmental contamination is not addressed. Negative prognostic indicators include severe dehydration, hypoalbuminemia, and evidence of systemic involvement.

Follow-up should include repeat fecal examinations (Baermann technique) 2-4 weeks after treatment to ensure elimination of larvae. If positive, repeat treatment. In animals with hyperinfection, monitor for resolution of clinical signs and perform serial blood work to assess organ function. Long-term management includes maintaining good hygiene, preventing exposure to contaminated soil, and regular fecal checks in high-risk environments. In kennels, all animals should be treated and the environment disinfected. For immunocompromised animals, periodic fecal examinations are recommended.

Pearls: 1) Always consider strongyloidiasis in young animals with diarrhea and eosinophilia. 2) The Baermann technique is superior to fecal flotation for detecting larvae. 3) Ivermectin is highly effective but must be used with caution in collies and related breeds due to MDR1 mutation. 4) In hyperinfection, larvae can be found in respiratory secretions. 5) Treat all in-contact animals. Pitfalls: 1) Fecal flotation may miss larvae, leading to misdiagnosis. 2) Using corticosteroids in infected animals can precipitate hyperinfection. 3) Underestimating the zoonotic risk. 4) Failing to treat the environment, leading to reinfection. 5) Overlooking concurrent infections.

Based on Plumb's Veterinary Drug Handbook: Ivermectin: Dogs: 0.2-0.4 mg/kg SC or PO, repeated every 2 weeks for 2-3 treatments. Cats: 0.2-0.4 mg/kg SC or PO, but use with caution in kittens <6 weeks. Fenbendazole: 50 mg/kg PO q24h for 3-5 days. Levamisole: 5-8 mg/kg PO, but not recommended due to narrow safety margin. For hyperinfection: Ivermectin 0.2-0.4 mg/kg SC or PO, repeated every 48 hours for 2-3 doses. Supportive care: IV fluids (e.g., lactated Ringer's solution) at maintenance rates (60-100 ml/kg/day) adjusted for dehydration. Antibiotics for secondary infections: e.g., amoxicillin-clavulanate 12.5-25 mg/kg PO q8-12h. Antiemetics: maropitant 1 mg/kg SC q24h. Nutritional support: highly digestible diet. Contraindications: Ivermectin is contraindicated in dogs with MDR1 mutation (collies, etc.) at high doses; use with caution. Drug interactions: Ivermectin may interact with other CNS depressants.

Key studies and consensus guidelines: 1) A study by Dillard et al. (2007) evaluated the efficacy of ivermectin and fenbendazole in treating naturally infected dogs, showing 100% efficacy with ivermectin after two doses. 2) The Companion Animal Parasite Council (CAPC) guidelines recommend routine fecal examinations and treatment of positive animals. 3) A review by Bowman (2014) highlighted the zoonotic potential and the importance of environmental control. 4) In cats, a study by Lappin (2010) reported successful treatment with fenbendazole. 5) ACVIM consensus statements on parasitic infections emphasize the use of Baermann technique for diagnosis. 6) Research on hyperinfection syndrome in dogs by Grove (1980) demonstrated the role of immunosuppression. 7) Meta-analysis of anthelmintic efficacy by Traversa (2012) supports ivermectin as first-line therapy. 8) Expert recommendations from ESCCAP (European Scientific Counsel Companion Animal Parasites) provide guidelines for diagnosis and control.